🇺🇸 FDA

Intelligence Platform

Patents

Browse 45 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10988465

CXCR4 inhibitors and uses thereof

X4 Pharmaceuticals, Inc. · Granted Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10953003

Methods for treating cancer

X4 Pharmaceuticals, Inc. · Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10851173

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System · Granted Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10759796

CXCR4 inhibitors and uses thereof

X4 Pharmaceuticals, Inc. · Granted Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10633442

Antibodies to connexin 43 (Cx43) hemichannels and methods of use thereof to inhibit Cx43 h

The Board of Regents of the University of Texas System · Granted Tue Apr 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10610527

Methods for treating immunodeficiency disease

X4 Pharmaceuticals, Inc. · Granted Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10548889

Compositions of CXCR4 inhibitors and methods of preparation and use

X4 Pharmaceuticals, Inc. · Granted Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10537560

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10538763

Compounds and methods for modulation of DUX4

Ionis Pharmaceuticals, Inc. · Granted Tue Jan 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10342786

P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Fulcrum Therapeutics, Inc. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10273307

Humanized anti-CD134 (OX40) antibodies and uses thereof

Biocerox Products B.V. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10196450

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9914775

Methods for treating inflammatory disorders or cancer metastasis by administering antibodi

The Board of Regents of the University of Texas System · Granted Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9828432

Cancer treatment and monitoring methods using OX40 agonists

Providence Health & Services—Oregon · Granted Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9790281

Humanized anti-CD134 (OX40) antibodies and uses thereof

Biocerox Products B.V. · Granted Tue Oct 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9695246

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System · Granted Tue Jul 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 29 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9527917

Nucleic acid encoding anti-OX40 antibodies

The Board of Regents of the University of Texas System · Granted Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9475880

Anti-CD134 (OX40) antibodies and uses thereof

Biocerox Products B.V. · Granted Tue Oct 25 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9163085

Anti-OX40 antibodies and methods of treating cancer

The Board of Regents of the University of Texas System · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9006399

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System · Granted Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 7959925

Trimeric OX40-immunoglobulin fusion protein and methods of use

Providence Health System · Granted Tue Jun 14 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

granted